


IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In re Patent Application of
Takashi YOSHITAKE et al.

Serial No. 10/594,436

Filed: September 26, 2006

Atty. Ref.: 1050-4

TC/A.U.: To be assigned

Examiner: To be assigned

For: CONTROLLED-RELEASE PHARMACEUTICAL COMPOSITION
AND METHOD FOR PRODUCING THE SAME

* * * * *

January 17, 2007

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Applicants bring to the attention of the Patent and Trademark Office the documents listed on the attached form PTO/SB/08a. Copies of the non-U.S. documents are attached.

Attention is also directed to copending applications Serial Nos. 10/849,544 and 11/543,991.

The Examiner is requested to initial the attached form PTO/SB/08a and to return a copy of the initialed document to the undersigned as an indication that the listed documents have been considered and made of record.

You are hereby authorized to charge any further expense in connection with this Submission to our deposit account No. 14-1140 for any fees required in connection with the filing of this paper.

Takashi YOSHITAKE et al.
Serial No. 10/594,436

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: _____



Arthur R. Crawford
Reg. No. 25,327

ARC:eaw
901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

1050-4

10/594,436

APPLICANT

Takashi YOSHITAKE et al.

(Use several sheets if necessary)

FILING DATE

GROUP

September 26, 2006

To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,362,424 B	11/1994	Debregeas et al			
	5,260,068 B	11/1993	Chen			
	5,260,069 B	11/1993	Chen			
	4,980,170 B	12/1990	Schneider et al			
	5,567,441 B	10/1996	Chen			
	5,229,131 B	7/1993	Amidon et al			
	4,083,949	4/1978	Benedikt			
	2005/0163846	7/2005	Aoki			

FOREIGN PATENT DOCUMENTS

DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
WO 97/02020	1/1997	PCT			
0 519 365 A1	6/1992	EP			
0 793 959 A1	9/1997	EP			
DE 4 219 390 A1	12/1992	Germany			
WO 97/25979	7/1997	PCT			
WO 99/32093	7/1999	PCT			
01-193215 A	8/1989	JAPAN			ABSTRACT
WO 97/48380	12/1997	PCT			
2001-511443	08/2001	JP			
0 447 168 A2	09/1991	EP			
0 386 967 A2	09/1990	EP			
59-44311	03/1984	JP			
0 888 772 A1	01/1999	EP			
1 004 305 A1	05/2000	EP			
253999	7/1996	New Zealand			
517465	10/2003	New Zealand			
0 244 380	11/1987	EP			
1 010 423 A2	6/2000	EP			
0 502 032 B1	3/1994	EP			

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

	Orr, "Therapeutic Options in the Treatment of Nighttime Gastroesophageal Reflux", Digestion 2005; 72:229-238; DOI 10.1159/000089957.
	Shimatani et al, "Rabeprazole 10 mg twice daily is superior to 20 mg once daily for night-time gastric acid suppression", Aliment Pharmacol Ther 2004; 19: 113-122; doi 10.1046/j.1365-2036.2003.01821.x.
	Kwakye et al, "Gamma scintigraphic evaluation of film-coated tablets intended for colonic or biphasic release", International Journal of Pharmaceutics 270 (2004) 307-313.
	Abrahamsson et al, "Gastro-intestinal transit of a multiple-unit formulation (metoprolol CR/ZOK) and a non-disintegrating tablet with the emphasis on colon", International Journal of Pharmaceutics 140 (1996) 229-235.

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Initial this form with next communication to application.

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

1050-4

10/594,436

APPLICANT

Takashi YOSHITAKE et al.

(Use several sheets if necessary)

FILING DATE

TC/A.U.

September 26, 2006

To be assigned

U.S. Serial No. 11/543,991

U.S. Serial No. 10/849,544.



*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.